Pre-market Hot Trades in US Stocks
Innodata, up 8.88% in pre-market trading, has no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Leifras is up 8.19% in pre-market trading. Based on recent key news:
<ol>
<li>On January 29, Leifras announced it has secured a contract in Membe City, Hokkaido, to provide management and operation services for community club activities at the city’s junior high school. This contract runs from April 2026 to March 2029, supporting the transition of club activities from schools to the community. This news drove Leifras' stock price up 8.19%. Industry policies support the development of community services.</li>
</ol>
Top Gainers in Pre-market US Stocks
TEN is up 67.82% in pre-market trading. Based on recent news:
<ol>
<li>
On January 27, TEN Holdings announced it successfully raised funds to repay debts and regained compliance with Nasdaq. This news boosted market confidence, significantly driving up the stock price.
</li>
<li>
On January 26, analysts rated TEN Holdings as neutral; despite the company's weak financial performance, recent corporate actions provided some support.
</li>
<li>
On January 25, technical signals for TEN Holdings indicated a strong sell, but the market remains cautious about its future prospects. Recent market volatility requires investors to be prudent.
</li>
</ol>
Serina Therapeutics is up 37.87% in pre-market trading. Based on recent key news:
<ol>
<li>
On January 28, Serina Therapeutics announced that its drug SER-252 for treating advanced Parkinson's disease received IND application approval from the FDA. This news significantly boosted the stock price, reflecting market optimism about the drug's potential commercial success. Source: Reuters
</li>
<li>
On January 29, Benzinga's stock ranking indicated that Serina Therapeutics' price trend is negative across all time frames. This may affect investor sentiment but did not prevent a short-term rise in stock price. Source: Benzinga
</li>
<li>
On January 28, the company detailed in its annual report how regulatory decisions could impact the drug's labeling, manufacturing process, safety, and other factors, which may affect the drug's commercial potential. Source: Company announcement. Recent policy support in the biotechnology industry has led to significant capital inflows.
</li>
</ol>
DCX is up 30.39% in pre-market trading. Based on recent key news:
<ol>
<li>
On January 29, Digital Currency X Technology received a notice from Nasdaq confirming it has regained compliance and meets the minimum market capitalization requirements for listed securities. This news drove the stock price up
</li>
<li>
On January 26, the company implemented a 12-for-1 stock consolidation to restore compliance with Nasdaq's minimum bid requirements. This move boosted market confidence and facilitated a rise in stock prices.
</li>
<li>
On January 27, despite the company having received a delisting notice from Nasdaq, subsequent compliance news alleviated market concerns, leading to a rebound in stock prices. The digital asset management industry has performed strongly recently
</li>
</ol>

INOD

Innodata pre-market up 8.88%; Leifras pre-market up 8.19%; TEN pre-market up 67.82%; Serina Therapeutics pre-market up 37.87%; Digital Currency X Tech pre-market up 30.39%

Hot pre-market trades in US stocks: Innodata up 8.88% pre-market; Leifras up 8.19% pre-market